NĀ HAʻAWINA HIHIA O KĒIA MANAWA
CAR-T no Glioblastoma
ʻO Glioblastoma kekahi o nā puʻupuʻu lolo mua maʻamau a paʻakikī hoʻi i nā pākeke. Hoʻomaka ia mai nā pūnaewele glial i loko o ka lolo a ua ʻike ʻia no kona ulu wikiwiki ʻana a me ke ʻano e komo i loko o nā ʻiʻo a puni, e paʻakikī ai ka wehe ʻana. Hiki i nā hōʻailona ke komo pū me nā poʻo ʻeha, nā hopu ʻana, nā loli noʻonoʻo, a me nā hemahema neurological, ma muli o ka wahi o ka puʻupuʻu. ʻOiai hiki i nā lāʻau lapaʻau maʻamau ke kōkua i ka mālama ʻana i ka maʻi, nui nā maʻi e ʻimi nei i nā lāʻau lapaʻau i kuhikuhi ʻia e hoʻomaikaʻi i nā hopena a me ke ʻano o ke ola.
Lapaʻau CAR-T no ke Kanesa ʻōpū
ʻO ka CAR-T cell therapy kahi immunotherapy pilikino hou loa e hoʻohana ikaika ʻia nei i ka mālama ʻana i ka maʻi ʻaʻai gastric. Ua hoʻomohala ʻo BIOOCUS i nā huahana CAR-T e pili ana i nā antigens kikoʻī no ka maʻi ʻaʻai gastric e like me Claudin18.2 a me HER2, e hōʻike ana i ka pono koʻikoʻi i nā poʻe maʻi i hāʻule i nā lāʻau lapaʻau mua he nui—no ka laʻana, ua loaʻa iā CT041 kahi ORR o 57.1%, DCR o 75%, a me ka helu ola holoʻokoʻa 6 mahina o 81.2%. Ma ka hoʻohana ʻana i kahi kahua GMP-grade honua, kahi hui loea multidisciplinary, a me ka ʻike lapaʻau honua ākea, hāʻawi ʻo BIOOCUS i kahi hopena CAR-T palekana, pono, a piha no nā poʻe maʻi ʻaʻai gastric.
CAR-T no ka Systemic Lupus Erythematosus (SLE)
ʻO ka lāʻau lapaʻau cell CAR-T (Chimeric Antigen Receptor T) kahi immunotherapy hou i hōʻike i ka hiki ke mālama i ka SLE ma o ka hoʻopaʻa ʻana i nā cell B, kahi e pāʻani nei i kahi kuleana koʻikoʻi i ka pathogenesis o ka maʻi. I ka SLE, hana nā cell B i nā autoantibodies e hoʻouka i nā ʻiʻo o ke kino, e alakaʻi ana i ka mumū mau a me ka hōʻino ʻana o nā ʻōkana. Hana ka lāʻau lapaʻau CAR-T ma ka ʻenekinia ʻana i nā cell T e hōʻike i kahi receptor (CAR) e hoʻopaʻa pono ana iā CD19, kahi māka ma nā cell B, e alakaʻi ana i ka luku ʻia ʻana o kēia mau cell B ʻino.
ʻO nā pūnaewele CAR-T e kuhikuhi ana i nā pūnaewele CD19+ B e hāʻawi i ka hoʻopau ʻana o nā pūnaewele B i ʻoi aku ka maikaʻi a me ka hoʻomau ʻana i hoʻohālikelike ʻia me nā lāʻau lapaʻau ʻē aʻe, kahi e kuhikuhi ana iā CD20 akā ʻaʻole hiki ke hoʻopau i nā pūnaewele plasma lōʻihi. Hiki i kēia hoʻopau nui ʻana o nā pūnaewele B ke alakaʻi i ka hoʻomaha ʻana o nā hōʻailona SLE ma ka hoʻopau ʻana i nā pūnaewele kuleana no ka hana ʻana o ka autoantibody. Ke nānā pū nei nā haʻawina iā CAR-Treg (nā pūnaewele CAR-T i hoʻolālā ʻia e hoʻoponopono i nā pane pale) e hoʻihoʻi i ka hoʻomanawanui pale a hōʻemi i ka hana autoimmune.
FUCASO: ʻO ka lāʻau lapaʻau BCMA CAR-T kanaka piha me ka pono a me ka palekana i kūlike ʻole
He lāʻau lapaʻau CAR-T kipi ʻo FUCASO e IASO BIO e pili ana i ka BCMA, e hāʻawi ana i ka pono a me ka palekana ʻole no ka myeloma multiple relapsed a refractory paha. Me nā helu pane kiʻekiʻe, ke kala mau loa, a me kahi ʻano palekana paʻa, hāʻawi ʻo FUCASO i ka manaʻolana hou no nā maʻi a hoʻokumu i kahi kūlana hou i ka lāʻau lapaʻau CAR-T.
He ʻIkepili Holoʻokoʻa o ka Lapaʻau Leukemia Hou
ʻO ka CAR-T Therapy, pōkole no Chimeric Antigen Receptor T-Cell Immunotherapy, he ʻano hana lapaʻau gene holomua e pili ana i ka hoʻololi ʻana i nā pūnaewele T ponoʻī o ka mea maʻi e kuhikuhi a luku i nā pūnaewele kanesa. ʻAʻole e like me nā lāʻau lapaʻau kuʻuna, ua hana kūikawā ʻia ka CAR-T therapy no kēlā me kēia mea maʻi a koi ʻia ka hōʻiliʻili ʻana i nā pūnaewele T mai ke koko o ka mea maʻi ma mua o ka hoʻihoʻi ʻana iā lākou i loko o ke kino ma hope o ka ʻenekinia genetic.